Tag Archives: Mindy Kitei

Ampligen: The FDA’s Unequal Treatment of a Second-Class-Citizen Drug

On December 11, 2013, I wrote a letter to the FDA’s Director of the Center for Drug Evaluation and Research, Dr. Janet Woodcock. I pleaded with her to use her considerable discretion and potentially accelerated procedures regarding the approval of … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , | 8 Comments

“I have a plane to catch”

I am still working through all the emotions triggered by the highly anticipated December 20, 2012 FDA Arthritis Advisory Committee meeting about the approval of Ampligen, an immune-modulatory drug that has been very successful in treating a sub-group of myalgic … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , | 66 Comments